Page 26 - 2020_08-Haematologica-web

T. Barbui et al.
References
1. Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129(24):3227-3236.
2. Rumi E, Boveri E, Bellini M, et al. Clinical course and outcome of essential thrombo- cythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diag- nostic criteria. Oncotarget. 2017;8(60): 101735-101744.
3. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109 (6):2310-2313.
4. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous throm- bosis in WHO-defined essential thrombo- cythemia: An international study of 891 patients. Blood. 2011;117(22):5857-5859.
5. Guglielmelli P, Carobbio A, Rumi E, et al. Validation of the IPSET score for thrombo- sis in patients with prefibrotic myelofibro- sis. Blood Cancer J. 2020;10(2):21.
6. Finazzi G, Vannucchi AM, Barbui T. Prefibrotic myelofibrosis: treatment algo-
rithm 2018. Blood Cancer J. 2018;8(11):104.
7. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essen- tial thrombocythemia are significantly influenced by accurate morphologic diag- nosis: A international study. J Clin Oncol. 2011;29 (23):3179-3184.
8. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transforma- tion in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507- 2513.
9. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-enhanced internation- al prognostic score system for transplanta- tion-age patients with primary myelofibro- sis. J Clin Oncol. 2018;36(4):310-318.
10. Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognos- tic systems for essential thrombo- cythaemia and polycythaemia vera. Br J Haematol. 2020 Jan 16. [Epub ahead of print].
11. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET- thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.
12. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombo- sis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-5133.
13. VannucchiAM,AntonioliE,GuglielmelliP, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with poly- cythemia vera or essential thrombo- cythemia. Blood. 2007;110(3):840-846.
14. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classi- cal myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057-1069.
15. BarbuiT,CarobbioA,RumiE,etal.Tothe editor: In contemporary patients with polycythemia vera, rates of thrombosis
and risk factors delineate a new clinical epidemiology. Blood. 2014;124(19):3021- 3023.
16. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in poly- cythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132-143.
17. Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am J Hematol. 2017;92(11):1131-1136.
18. Enblom-Larsson A, Girodon F, Bak M, et al. A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. Br J Haematol. 2017;177(5):800-805.
19. Gisslinger H, Zagrijtschuk O, Buxhofer- Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNa-2b, induces high response rates with low toxicity in patients with poly- cythemia vera. Blood. 2015;126(15):1762- 1769.
20. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD- PV and CONTINUATION-PV): a ran- domised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):196-e208.
21. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment out- come of blast phase BCR-ABL - myelopro- liferative neoplasms. Blood. 2008;112(5):1628-1637.
22. Tefferi A, Mudireddy M, Mannelli F, et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018;32(5) :1200-1210.
23. Björkholm M, Derolf ÅR, Hultcrantz M, et al. Treatment-related risk factors for trans- formation to acute myeloid leukemia and myelodysplastic syndromes in myelopro- liferative neoplasms. J Clin Oncol. 2011;29 (17):2410-2415.
24. Mascarenhas J, Lu M, Kosiorek H, et al. Oral idasanutlin in patients with poly- cythemia vera. Blood. 2019;134(6):525- 533.
25. Rambaldi A, Iurlo A, Vannucchi AM, et al. Safety and efficacy of the maximum toler- ated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia. 2020 Feb 11. [Epub ahead of print].
26. Odenike O. How I treat the blast phase of Philadelphia chromosome-negative myelo- proliferative neoplasms. Blood. 2018;132(22):2339-2350.
27. McKenney AS, Lau AN, Somasundara AVH, et al. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Invest. 2018; 128(2):789-804.
28. Lancet JE, Uy GL, Cortes JE, et al. Cpx-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytara- bine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684-2692.
29. Barbui T, De Stefano V, Ghirardi A, Masciulli A, Finazzi G, Vannucchi AM. Different effect of hydroxyurea and phle- botomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood Cancer J. 2018;8(12):124.
30. De Stefano V, Carobbio A, Di Lazzaro V, et al. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J. 2018;8(3):25.
31. De Stefano V, Rossi E, Carobbio A, et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018;8(11):112.
32. De Stefano V, Vannucchi AM, Ruggeri M, et al. Splanchnic vein thrombosis in myelo- proliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6(11):e493.
33. Sant’Antonio E, Guglielmelli P, Pieri L, et al. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. Am J Hematol. 2020;95(2):156-166.
34. Masciulli A, Ferrari A, Carobbio A, Ghirardi A, Barbui T. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analy- sis. Blood Adv. 2020;4(2):380-386.
35. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45.
36. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombo- cythemia: the ANAHYDRET Study, a ran- domized controlled trial. Blood. 2013;121(10):1720-1728.
37. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. N Engl J Med. 2004;350 (2):114-124.
38. Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and risks of antithrom- botic therapy in essential thrombo- cythemia: A systematic review. Ann Intern Med. 2017;167(3):170-180.
39. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosyn- thesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595- 3603.
40. Dillinger JG, Sollier CBD, Sideris G, Ronez E, Henry P, Drouet L. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res. 2012;129(1):91-94.
41. De Stefano V, Rocca B, Tosetto A, et al. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II ran- domized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer J. 2018;8(6):49.
42. Rocca B, Tosetto A, Betti S, et al. A ran- domized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020 april 7. [Epub ahead of print]
43. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombo- cythemia: Incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372-380.
44. Hernández-Boluda J-C, Arellano-Rodrigo E, Cervantes F, et al. Oral anticoagulation to prevent thrombosis recurrence in poly-
2002
haematologica | 2020; 105(8)